A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To study the tolerance and safety of increasing doses of AL-721 in patients with persistent
generalized lymphadenopathy (PGL) and symptomatic HIV infection, and to obtain preliminary
information on the effectiveness of AL-721 against the human immunodeficiency virus (HIV) in
HIV-infected persons with PGL and symptomatic HIV infection. Although zidovudine (AZT)
prolongs life in certain AIDS patients, it is not a cure for AIDS and it also has toxic
effects in many patients. Therefore, it is necessary to test other drugs in HIV-infected
patients. AL-721 is a mixture of lipids (fats) extracted from egg yolks. Laboratory tests
suggest that it might inhibit the infectivity of the HIV. AL-721 has been tried so far in a
few patients for short periods of time and has been found to be well tolerated.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)